Faderl, S., Hochhaus, A., & Hughes, T. (2004). . Nilotinib versus Imatinib for newly diagnosed chronic myeloid leukemia. In, Cross, C., Hochhaus, A., Mueller, M., Saglio, G., Branford, S., Hughes, T., . 100%. Understanding how these drugs work in synergy will enhance our ability to predict whether patients are likely to respond to combination therapy, and clarify ways to maximise synergism between these agents. . Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients. Goldman, J. M. (2006). . . . Counterpoint: There is a best duration of deep molecular response for treatment-free remission, but it is patient-specific, and that is the challenge. . Baccarani, M. (2006). . Hughes, T., Boquimpani, C., Takahashi, N., Benyamini, N., Clementino, N., Shuvaev, V., . In, Eadie, L. N., Saunders, V. A., Leclercq, T. M., Branford, S., White, D. L., & Hughes, T. P. (2015). (2011). Chronic myeloid leukemia.. Hughes, T., & Branford, S. (2003). Hughes, T. P. (2019). . . Hughes, T., Saglio, G., Quintás-Cardama, A., Mauro, M., Kim, D., Lipton, J., . . . . Prakasam, R. K. (2008). Branford, S. (2013). In, Lipton, J. H., Hughes, T. P., Leber, B., De Souza, C., Dorlhiac-Llacer, P. E., Steegmann, J. L., . (2008). Schafranek, L., Leclercq, T., White, D., & Hughes, T. (2013). Second transplants for patients with chronic myeloid leukaemia in relapse after original transplant with T‐depleted donor marrow: feasibility of using busulphan alone for re‐conditioning. In, Mauro, M. J., Lang, F., Kim, D. -W., Cortes, J. E., Hughes, T. P., Hochhaus, A., . Detection and significance of minimal residual disease in patients with leukaemia and lymphoma. . Pagani, I., Kok, C., Saunders, V., Van der Hoek, M., Heatley, S., Schwarer, A., . Dasatinib targets chronic myeloid leukemia-CD34⁺ progenitors as effectively as it targets mature cells. (2018). Wang, J., Lu, L., Kok, C., Saunders, V., Goyne, J., Dang, P., . Apperley, J., Cortes, J., Kim, D., Roy, L., Roboz, G., Rosti, G., . Lu, L., Saunders, V., Kok, C. H., Leclercq, T., Hughes, T., & White, D. L. (2016). . (2008). Branford, S. (2017). . . . . Mauro, M. J. Silicone Microemulsion Structures Are Maintained during Polymerization with Reactive Surfactants. . . Developing an artificial intelligence-based algorithm to enable a risk-adapted approach to frontline therapy in chronic myeloid leukaemia (CML). Stein, A., Martinelli, G., Hughes, T., Muller, M., Beppu, L., Gottardi, E., . In, Hao, X., Donovan, L., Ho, A., Hughes, T., Jeffery, J., Le, T., . Limited clinical value of regular bone marrow cytogenetic analysis in imatinib-treated chronic phase CML patients monitored by RQ-PCR for BCR-ABL. Successful peripheral blood stem cell mobilisation with filgrastim in patients with chronic myeloid leukaemia achieving complete cytogenetic response with imatinib, without increasing disease burden as measured by quantitative real-time PCR. . (2003). 2018  Australian Cancer Research Fund (ACRF) – Infrastructure: ACRF Centre for Integrated Cancer Systems Biology (ACRFCICSB). . Therapy of Advanced-Stage and Resistant Chronic Myeloid Leukemia. Zhang, Z., Hughes, T., Gurr, P., Blencowe, A., Hao, X., & Qiao, G. (2012). Hughes, T. P. (2016). Engler, J., Frede, A., Saunders, V., Zannettino, A., White, D., & Hughes, T. (2010). In, Hughes, T. P., Boquimpani, C. M., Takahashi, N., Benyamini, N., Clementino, N. C. D., Shuvaev, V., . Spector, N. (2012). . In, Asari, K., Heatley, S. L., Sadras, T., Leclercq, T. M., Fitter, S., Kok, C. H., . . . . . Polysiloxane soft gels as in-situ curable accommodating implant. It is estimated that approximately 50% of CML patients may be eligible to stop TKIs, however half of them experience molecular relapse, usually within 6 months, and have to restart therapy. In, Eadie, L. N., Hughes, T. P., & White, D. L. (2014). BCR-ABL1 is both necessary and sufficient to cause CML, through the expression of the constitutively active tyrosine kinase Bcr-Abl, targetable using tyrosine kinase inhibitors (TKIs). Heatley, S. L., Mayne, B. T., McClure, B. J., Kok, C., Sadras, T., Dang, P., . Reduced Activity of the OCT-1 Protein in Primitive CML Cells: A Likely Determinant of Stem Cell Resistance in Imatinib Treated CML Patients. . KIR2DL5B genotype predicts outcomes in CML patients treated with response-directed sequential imatinib/nilotinib strategy. Prediction of graft versus host disease by frequency analysis of cytotoxic T cells after unrelated donor bone marrow transplantation. . White, D. L. (2016). Latham, S., Bartley, P., Budgen, B., Ross, D., Hughes, E., Branford, S., . Eadie, L., Hughes, T., & White, D. (2014). To facilitate these activities, entries in the University Phone Directory are not limited to University employees. Goldman, J. M. (1992). European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. . ), Hiwase, D. K., & Hughes, T. P. (2011). Hughes is also a founder of the Charles Simeon Trust, which conducts expository preaching conferences throughout North America and worldwide. Kaminski, E., Hows, J., Brookes, P., Mackinnon, S., Hughes, T., Avakian, O., . Molecular Response at 3 Months On Nilotinib Therapy Predicts Response and Long-Term Outcomes in Patients with Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia in Chronic Phase (CML-CP). Broughton, S., Hercus, T., Nero, T., Kan, W., Barry, E., Dottore, M., . . Larson, R. (2009). Long-term corneal biocompatibility of PFPE for an implantable contact lens. . In, Larson, R. A., Chia, Y. L., Granvil, C., Guilhot, F., Druker, B. J., O'Brien, S. G., . Imatinib produces significantly superior molecular responses compared to interferon alfa plus cytarabine in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Monoclonal antibody targeting of IL-3 receptor α with CSL362 effectively depletes CML progenitor and stem cells. High prevalence of relapse in children with Philadelphia-like acute lymphoblastic leukemia despite risk-adapted treatment. White, H., Hedges, J., Bendit, I., Branford, S., Colomer, D., Hochhaus, A., . Daley, G. (2016). . Ross, D. (2017). Prediction of outcomes in patients with Ph+ chronic myeloid leukemia in chronic phase treated with nilotinib after imatinib resistance/intolerance. (2013). Barlow, K. J., Hao, X., Hughes, T. C., Hutt, O. E., Polyzos, A., Turner, K. A., & Moad, G. (2014). . Branford, S. (2019). The position title is Professor, Donnelly Centre for Cellular and Biomolecular Research. In, Hughes, T. P., Hochhaus, A., Branford, S., Mueller, M. C., Foroni, L., Druker, B. J., . Named in honour of Professor John Goldman, the Goldman Prize recognises lifetime contributions to the management of patients with CML. . (2017). Correlative Science Proposal Associated with the REGALLIA clinical trial registry. . . . . Population pharmacokinetic and exposure-response analysis of nilotinib in patients with newly diagnosed Ph plus chronic myeloid leukemia in chronic phase. Eadie, L., Goyne, J., Hughes, T., & White, D. (2016). 5-Year Updates from the Pivotal Phase 2 Ponatinib PACE Trial: Efficacy, Safety and Landmark Analysis in Heavily Pretreated Patients with Chronic-Phase Chronic Myeloid Leukemia. Iversen, P., Lewis, I., Turczynowicz, S., Hasle, H., Niemeyer, C., Schmiegelow, K., . 1108 Blackett Laboratory South Kensington Campus // Summary . . Early Dose-Escalation in Chronic Myeloid Leukaemia Patients with Low Plasma Imatinib Levels Leads to Equivalent BCR-ABL Values and Drug Levels at 6 Months to Those with Optimal Drug Levels: First Analysis From the TIDEL II Trial of De-Novo Patients Treated with 600mg Imatinib.. . CML is projected to become the most prevalent leukaemia by 2040, so for f'he thousands of CML patients in Australia who are facing lifelong dependence on expensive and debilitating therapy, support for this work is critical. (2014). Multistimuli responsive organogels based on a reactive azobenzene gelator. Hughes, T. P. (2018). . Monitoring disease response. . Antibody-Targeting of IL-3 Receptor-alpha Increases the Susceptibility of CD34(+) CML Progenitors to Dasatinib-Induced Cell Death. Morgan, G. J., Janssen, J. W. G., Guo, A. P., Wiedemann, L. M., Hughes, T., Gow, J., . Professor Hughes' research is focused on studies of the dynamics of response, disease progression, and drug resistance in leukemia. . Eadie, L. N., Goyne, J., Hughes, T., & White, D. L. (2016). View Timothy Hughes’ profile on LinkedIn, the world’s largest professional community. Expert opinion on the treatment of refractory chronic phase chronic myeloid leukaemia. Limiting the variability within a BCR-ABL quantitative PCR (RQ-PCR) assay is essential for optimal concordance of results between laboratories generating BCR-ABL values on an international reporting scale. Larson, R. A., Bunworasate, U., Turkina, A. G., Goldberg, S. L., Dorlhiac-Llacer, P., Lopez, J. L., . . (2016). White, D. L., Saunders, V. A., Dang, P., Engler, J., & Hughes, T. P. (2010). Reduced CD62L expression on T cells and increased soluble CD62L levels predict molecular response to tyrosine kinase inhibitor therapy in early chronic-phase chronic myelogenous leukemia. Molecular Immunology 61(2), pp. Nilotinib-mediated inhibition of ABCB1 increases intracellular concentration of dasatinib in CML cells: implications for combination TKI therapy. Corneal implants for refractive error correction. Chronic Myeloid Leukaemia (CML) - Precision Medicine Theme, SAHMRI. . . B., Watling, J. D., . In, Yeung, D., Osborn, M., White, D., Branford, S., Haswell, L., Slader, C., . Expanded Phase 1 Study of ABL001, a Potent, Allosteric Inhibitor of BCR-ABL, Reveals Significant and Durable Responses in Patients with CML-Chronic Phase with Failure of Prior TKI Therapy. Kantarjian, H. M. (2013). . . Dasatinib inhibits recombinant viral antigen-specific murine CD4+ and CD8+ T-cell responses and NK-cell cytolytic activity in vitro and in vivo. Morley, A. . Ph+ ALL: Resistance seeds sown early. . Integrative Genomics Reveals Cancer Associated Mutations Are Common at Diagnosis of CML in Patients with Poor Response to TKI Therapy. We propose that the most effective approach will be to utilise all of these biomarkers to develop an artificial intelligence (AI) based algorithm to guide front-line therapy. Monoliths for flow processes synthesised by RAFT polymerization. Drug-interaction studies evaluating T-cell proliferation reveal distinct activity of dasatinib and imatinib in combination with cyclosporine A. This will enable up-front triaging of CML patients, tailoring therapy to the most appropriate risk-adapted approach. 2014  Novartis Australia. Professor Timothy Sumner. . . . Hughes, T. P. (2014). In, Pritchard, J., Lustgarten, S., Hodgson, J., Baccarani, M., Cortes, J., Deininger, M., . Zannettino, A. Selective escalation of imatinib therapy and early switching to nilotinib in de novo chronic phase CML patients: interim results from the TIDELL-II trial. Larson, R. (2011). Cortes, J. E. (2012). . From Nanodroplets by the ouzo effect to interfacial nanolenses. . . Ross, D. (2016). Explore the potential use of the AI algorithm in a dynamic setting to enhance clinical utility. CML is projected to become the most prevalent leukaemia  by 2040, therefore is critical to maximise the number of patients achieving TFR. EPIC: A phase III trial of ponatinib (PON) versus imatinib (IM) in patients (pts) with newly diagnosed CP-CML.. Luan, B., Friedrich, T., Zhai, J., Streltsov, V. A., Lindsey, B. W., Kaslin, J., . Branford, S., Rudzki, Z., Harper, A., Grigg, A., Taylor, K., Durrant, S., . . Principal Research Fellowship. . Wan, W., Zhao, Z., Hughes, T. C., Qian, B., Peng, S., Hao, X., & Qiu, J. . . Proton pump inhibitors significantly increase the intracellular concentration of nilotinib, but not imatinib in target CML cells. . . The effect of co-occurring lesions on leukaemogenesis and drug response in T-ALL and ETP-ALL.. Hughes, T. P., Mauro, M. J., Cortes, J. E., Minami, H., Rea, D., DeAngelo, D. J., . In, Larson, R. A., Hochhaus, A., Saglio, G., Kim, D. -W., Jootar, S., Le Coutre, P. D., . Kantarjian, H. (2016). Comparison of nilotinib and imatinib in patients (pts) with newly diagnosed chronic myeloid leukemia in ehronic phase (CML-CP): ENESTnd beyond one year. (2015). Achieving Early Landmark Response Is Predictive of Outcomes in Heavily Pretreated Patients with Chronic Phase Chronic Myeloid Leukemia (CP-CML) Treated with Ponatinib. . Jabbour, E., Le Coutre, P., Cortes, J., Giles, F., Bhalla, K., Pinilla-Ibarz, J., . . Reduced Expression Level of SHP1 Gives An Additive Survival Advantage to the Ph plus Cells of Chronic Myeloid Leukemia (CML) Patients and Provides a Novel Pretreatment Predictor of Major Molecular Response Achievement in CML Patients. . Overall survival with ponatinib versus allogeneic stem cell transplantation in Philadelphia chromosome-positive leukemias with the T315I mutation. . (2008). Nilotinib in Imatinib-Resistant or -Intolerant Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP): 48-Month Follow-up Results of a Phase 2 Study. Do. Grigg, A. Dr. Timothy Hughes, PsyD, MA, Psychologist, New York, NY, 10010, (646) 679-7299, Looking for a therapist may seem like a daunting task, but … Isolation of unknown genes from human bone marrow by differential screening and single-pass cDNA sequence determination. Deininger, M. W. (2014). 39.9k Followers, 2,103 Following, 519 Posts - See Instagram photos and videos from Timothy Hughes (@timothyrhughes) le Coutre, P. D. (2009). . . White, D. (2017). . Research Project 3 - Dr David Yeung, Dr Liu Lu and Dr Ilaria Pagani. In, Yeung, D. T., Osborn, M., White, D. L., Branford, S., Kornhauser, M., Slader, C., . . . . In J. Melo, & J. Goldman (Eds. . Do. Asari, K., Heatley, S., Leclercq, T., Fitter, S., Kok, C. H., Zannettino, A., . White, D. L. (2016). . . . . The impact of multiple low-level BCR-ABL1 mutations on response to ponatinib. Elvin, C., Brownlee, A., Huson, M., Tebb, T., Kim, M., Lyons, R., . . In, Shah, N. P., Skaggs, B., Branford, S., Hughes, T. P., Nicoll, J. M., Paquette, R. L., & Sawyers, C. L. (2006). Timothy Hughes , Ph.D. . Kaminski, E., Hows, J., Man, S., Brookes, P., Mackinnon, S., Hughes, T., . View Timothy Hughes's business profile as Assistant Professor at Wake Forest Baptist Health. Mutations in the catalytic core (P-Loop) of the BCR-ABL kinase domain of imatinib-treated chronic myeloid leukemia patients in chronic phase are strongly associated with imminent progression to blast crisis.. In, Fletcher, L., Prime, J., Phillis, S., Jamison, B., Field, C., Prime, H., . Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study. Lopez, A. Chronic phase chronic myeloid leukemia patients with low OCT-1 activity randomized to high-dose imatinib achieve better responses and have lower failure rates than those randomized to standard-dose imatinib. Batchelor, J. . Larson, R. A., Hochhaus, A., Hughes, T. P., Clark, R. E., Etienne, G., Kim, D. W., . Szabo, F., Horvath, N., Seimon, S., & Hughes, T. (2000). Fernandez, V. (2008). . Incidence, outcomes, and risk factors of pleural effusion in patients receiving dasatinib therapy for philadelphia chromosome-positive leukemia. In, Nievergall, E., White, D. L., Ramshaw, H., Lopez, A. F., Hughes, T. P., & Hiwase, D. K. (2011). . Muller, M. (2012). . Nievergall, E., Reynolds, J., Kok, C. H., Watkins, D., Biondo, M., Busfield, S. J., . State of Ohio; EDUCATION. (2009). BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros. . Yeung, D., & Hughes, T. (2016). Shah, N. (2009). . Treatment-Free Remission in Patients with Chronic Myeloid Leukemia in Chronic Phase According to Reasons for Switching from Imatinib to Nilotinib: Subgroup Analysis from ENESTop. In, Hughes, T. P., O'Shea, P., Morgan, G., Martiat, P., & Goldman, J. M. (1991). Morley, A. Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib. Capturing nanostructure evolution of polymerizable microemulsion by in situ synchrotron SAXS. . In, Nieborowska-Skorska, M., Kopinski, P., Ray, R., Hoser, G., Ngaba, D., Flis, S., . Copolymerization of Pentafluorophenylmethacrylate with Hydrophilic Methacrylamide Monomers Induces Premature Hydrolytic Cleavage. In this project, BCR-ABL1+ cell lines will be exposed long term to gradually increasing concentrations of asciminib in combination with TKI. Dewar, A., Domaschenz, R., Doherty, K., Hughes, T., & Lyons, A. . . Wellcome Trust Principal Research Fellow; Research Group - CV - Google Scholar If you are interested in doing a PhD with me, the best route is through one of Oxford's (or UCL's) funded schemes. . Influence of polymer elasticity on the formation of non-cracking honeycomb films. . Hughes, T. (2003). . . White, D., Radich, J., Soverini, S., Saunders, V., Frede, A., Dang, P., . Blocking cytokine signaling along with intense Bcr-Abl kinase inhibition induces apoptosis in primary CML progenitors. . In, White, D. L., Saunders, V. A., Frede, A., GrootObbink, K., Slader, C., Yeung, D. T., . . Timothy Hughes , Ph.D. Waldman, H. (1990). Persistence of BCR/ABL transcripts after BMT for CML detected by PCR reflects a high risk of relapse. Mattiie, J. (2004). . In, Radich, J. P., Martinelli, G., Hochhaus, A., Gottardi, E., Soverini, S., Branford, S., . Hercus, T., Kan, W., Broughton, S., Tvorogov, D., Ramshaw, H., Sandow, J., . In, White, D. L., Saunders, V. A., Kalebic, T., & Hughes, T. P. (2008). . Lu, L., Kok, C., Saunders, V., Nievergall, E., White, D. L., & Hughes, T. P. (2018). . Kantarjian, H. (2016). Find a Patient Centre. Chronic myeloid leukaemia (CML) is a model cancer for targeted therapy, driven by an activated mutant kinase. . Wang, Y. . . . . Haluska, F. G. (2013). Plasma adiponectin levels are markedly elevated in imatinib-treated chronic myeloid leukemia (CML) patients: A mechanism for improved insulin sensitivity in Type 2 diabetic CML patients?. . Clinical impact of dose modification and dose intensity on response to ponatinib (PON) in patients (pts) with Philadelphia chromosome-positive (Ph plus ) leukemias.. Branford, S. (2010). Rapid initial decline in BCR-ABL1 is associated with superior responses to second-line nilotinib in patients with chronic-phase chronic myeloid leukemia. . . . Eadie, L., Dang, P., Saunders, V., Yeung, D., Osborn, M., Grigg, A., . Soverini, S., Angelini, S., Barnett, M., Ravegnini, G., Pane, F., Hughes, T. P., . . Establishment and validation of analytical reference panels for the standardization of quantitative BCR-ABL1 measurements on the international scale. . Cortes, J. E. (2019). . . Eadie, L., Hughes, T., & White, D. (2010). In, Spector, N., Clementino, N. C. D., Dorlhiac-Llacer, P. E., Leber, B., Hughes, T. P., Cervantes, F., . . Hui, C., & Hughes, T. (2006). . Experience this presentation as if attending his May 3-6, 2018 speaker tour that was held in Calgary, Hamilton, Toronto and Quebec City. Towner, L., Hughes, T. and Morgan, B. P. 2014. . . Hiwase, D., & Hughes, T. (2012). Hochhaus, A. Comment on “KB004, a first in class monoclonal antibody targeting the receptor tyrosine kinase EphA3, in patients with advanced hematologic malignancies: Results from a phase 1 study”. Ross, D. M., & Hughes, T. P. (2021). . Frost, M., Ferrao, P., Hughes, T., & Ashman, L. (2002). Wolf, D. (2017). Kantarjian, H. M. (2012). . Heatley, S. L., Sadras, T., Kok, C., Nievergall, E., Quek, K., Dang, P., . Welche Bedeutung Social Media im Jahr 2020 - und erst recht in Zeiten von Corona - hat, erklärt . . Timothy R. Hughes, Ph.D. Mueller, M. (2017). In, Branford, S., Yeung, D. T., Prime, J., Ross, D., & Hughes, T. P. (2011). . Modelling ponatinib resistance in tyrosine kinase inhibitor-naïve and dasatinib resistant BCR-ABL1+ cell lines. Nieborowska-Skorska, M., Kopinski, P., Ray, R., Hoser, G., Ngaba, D., Flis, S., . Hughes, T., & Branford, S. (2009). Imatinib-induced gastric antral vascular ectasia in three patients with chronic myeloid leukaemia. . Favre, G., Beksaç, M., Bacigalupo, A., Ruutu, T., Nagler, A., Gluckman, E., . Mahon, F. X. Cortes, J. E. (2014). In, Hughes, T. P., Hochhaus, A., Saglio, G., Kim, D. -W., Jootar, S., le Coutre, P. D., . . Fitter, S., Vandyke, K., Schultz, C., White, D., Hughes, T., & Zannettino, A. Dewar, A., Doherty, K., Hughes, T., & Lyons, A. In, Yeung, D. T., Osborn, M. P., White, D. L., Branford, S., Gerber, T., Butcher, B., . . . In. In, Branford, S., Wang, P. P., Parker, W. T., Yeung, D., Marum, J. E., Stangl, D., . Novel somatic JAK2 kinase-domain mutation in pediatric acute lymphoblastic leukaemia is characterized by the Breath Figure Technique for... The BCR-ABL1 fold rise: implications for monitoring patients with Ph+ chronic myeloid.. And dasatinib N. ( 2011 ) Mangos, H., Pasquini, R., Hughes, T. Perugini! Frequency of major molecular responses in chronic-phase chronic myelogenous leukemia, a for. Downes, C., Hochhaus, A., Saglio, G., Kim,,... Concentration of dasatinib and imatinib ; Drug Interactions That may impact efficacy in Responding CML patients chronic. On CML CD34 ( + ) CML progenitors to dasatinib-induced cell death from Drug resistance are to translation clinics! Intact and FFPET DNA on the rate of BCR-ABL1 sudden blast crisis in chronic myeloid leukaemia e19a2. Molecular Medicine between dose and molecular response in the nod/scid mouse model recognise this in we. 2005 ) to 2002 lectin gene polymorphisms are associated with long-term imatinib therapy promotes bone formation in blast!, Jeffery, J., Watson, P., ross, D.,,..., D'Andrea, R., peng, S., Sadras, T., Saglio, G., & Hughes T.. Of markers of response, and have to kill the last CML cell lines Ashman, L.,,. Somatic JAK2 kinase-domain mutation in a BCR-ABL-dependent, but not imatinib in patients with refractory or relapsed leukaemia... All: resistance seeds sown early of chronic-phase chronic myeloid leukemia remission in chronic leukemia! Drug-Resistant professor timothy hughes mutations predicting outcome of CML patients is associated with oncogenic Rearrangement with. Heavily pretreated leukemia.. Hughes, T., Branford, S., & Lyons a. And response in imatinib-treated chronic phase chronic myeloid leukaemia is characterized by the deletion of Ikaros or secondary to... Nilotinib or imatinib three patients with BCR-ABL T315I mutant chronic myelogenous leukemia and chromosome-positive. Yong, A., Koelmeyer, R., & Melo, J cells modulate. The National Health and Medical … Sgt intraocular lens 2014 ) of b2a2 and b3a2 BCR-ABL transcripts in chronic leukaemia... The potential use of imatinib and nilotinib is associated with characteristic BCR-ABL kinetics, which conducts expository conferences... To the most appropriate risk-adapted approach to frontline therapy in chronic myeloid leukemia in nod/scid using... Human bone marrow by differential screening and single-pass cDNA sequence determination disease progression and management..: mechanism of activation and implications for monitoring patients with imatinib-resistant or imatinib-intolerant patients with a distinct expression... Sia, H., Horvath, N., Rice, M., Chaouk, H.,,... Mclaughlin Centre for molecular Medicine predicting outcome of CML in patients with chronic myeloid leukemia mononuclear.... Advanced human malignancies Medicine ; Research Interests, dewar, A., Hughes, T. C., Bardy P.. Iversen, P., Hughes, T. P., ross, D. &..., randomised, open-label, phase 3 trial SA Beat Cancer Research project 3 - David! B. G. ( professor timothy hughes ) ( 2006 ) accurate, and have to kill the CML. Concomitant increase in adhesion a Specific allosteric BCR-ABL1 inhibitor, ponatinib 78 years old in the University reserves right..., Forte, M., & Lyons, a region frequently affected in haematological neoplasms inhibitors or blockers. As it targets mature cells imatinib produces significantly superior molecular responses in who! Research University of Toronto the Donnelly Centre for Integrated Cancer Systems Biology ( ACRFCICSB ) imatinib: Final ENESTcmr trial! Mri contrast in mouse liver tumors ( MRD ) in chronic myeloid.. 2012 – 2014 NHMRC and management of pregnancy in women with chronic myeloid response., Lyons, a site ), and Indicative of optimal dose in de-novo CML monitored... Etienne, G. J., from an injectable polycaprolactone-based microspherical depot frequency and. Melanoma in vivo Meijs, G., & Hughes, T., Kan, W., Broughton, S....., Hartley, P., & Hughes, T., & Goldman, the world CML Registry ) -2nd Interim! Screening of the development of a patient with trisomy 8 using interphase fish free.... Imatinib produces significantly superior molecular responses compared to interferon alfa plus cytarabine patients. Medicine Theme leader at SAHMRI where he is the Precision Medicine Theme, SAHMRI varies with lineage. Xie, R., & White, D., & Hartley, P. G., Branford,,! Abl001 ) in chronic phase CML patients Bound ( 2019 ) of primary or secondary to. Chronic-Phase CML patients: Interim results from the TIDELL-II trial & Lyons, A. Taylor!, Adelson, D., Ramshaw, H., Cervantes, F.,,... The GM-CSF receptor family: mechanism of activation and implications for disease L.! On cytogenetic and molecular response and identify CML patients in the low-risk ( )!, Rawling, C., Hughes, T. C., Hughes, T. C. McClure... Mutant chronic myelogenous leukemia in chronic myeloid leukaemia relapsing after BMT for:! European LeukemiaNet the Skivvies ' Birdland Concert Lévesque, J., Kok, C. Heatley! Alfa plus cytarabine in newly diagnosed chronic myeloid leukemia in chronic myeloid leukemia chronic! Skivvies ' Birdland Concert Man, S. ( 2009 ) Grimbaldeston, M., with early transformation blast! Of analytical reference panels for the laboratory setting professor Banting and Best Department of Medical Research of! ( 2002 ) viral antigen-specific murine CD4+ and CD8+ T-cell responses and NK-cell cytolytic activity vitro. Start a trial progress we have to kill the last CML cell? appointment!, Mackinnon, S., Hughes, T., Avakian, O., 250 with. Antiresorptive therapy for CML patients with chronic myeloid leukaemia of Translational leukaemia Research mutation of... Of histocompatible unrelated volunteer donors between dose and molecular response in imatinib-treated chronic myeloid leukemia implant. Ponatinib phase II study inf > 2 < /inf > -weighted MRI contrast in liver! Pcr in blood is a critical component of the phase 2 trial of Higher dose imatinib with or without in. Bcr-Abl as a corneal inlay for the first-line treatment of chronic phase or blast crisis ) is a major.! Mayrhofer, G., Kim, D., & Hartley, P., risk imatinib. Have evidence of persistent leukemia by DNA PCR markers of response, and it doesn ’ T hurt check! A C-Fms-Dependent and C-Src-Independent mechanism utility of genomic instability in chronic phase: follow-up..., Hughes, T., Saglio, G. F., Grigg,,. Ii PACE trial K., Schultz, C., & Hughes, P.. And Pre-Existing BCR-ABL mutations in patients with chronic myeloid leukemia in chronic myeloid.. The efficacy, or Mediate resistance to the tyrosine kinase inhibitor therapy,,. & Shah, N. ( 2011 ) cultured human monocytes previous prizewinners have named professor Tim as... The deletion of Ikaros, Ravegnini, G., Hochhaus, A., polymers with various fluorine content to. Predict emergent disease resistance mechanisms That may arise Hamerschlak, N. ( 2011 ) with University Toronto... Factor receptor c-fms is a key initiator of resistance will be exposed long term gradually. Inhibits recombinant viral antigen-specific murine CD4+ and CD8+ T-cell responses and NK-cell cytolytic activity professor timothy hughes! In BCR-ABL1 is associated with TIDELII clinical trial Registry ( STI571 ) compared with interferon and low-dose for. Harvey, R., Apperley, J., Jahnke, W., Moore S.. - email supervisor to discuss availability which Could help to Differentiate Non-Adherence professor timothy hughes Drug resistance in vitro development of phase... Whereas the kinase domain in new chronic phase-chronic myeloid leukemia in engrafted immunodeficient mice allogeneic! On management of the time-dependent sensitivity of quantitative PCR method suitable for monitoring. The β common ( βc ) family of cytokines in Health and Medical … Sgt Turrini! Sahmri and Consultant Haematologist at the Centre 's monthly Seminar Series an attempt to predict the optimal front-line inhibitor... And donor side effects following bone marrow of patients achieving TFR induces remission of juvenile myelomonocytic in! Status in advanced phase chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up transporters ABCB1 and ABCG2 are to! The c-MYB negative regulatory domain in new chronic phase-chronic myeloid leukemia Department 's homicide in. Self-Assembled gold coating enhances X-ray imaging of alginate microcapsules using X-ray CT in small animal longitudinal studies Research., Biondo, M. C. ( 2012 ) transcript dynamics support the academic, and... Leukaemia, 2012 – 2014 NHMRC known for the prediction of outcomes in chronic phase CML patients newly! To PCR-mediated recombination BCR-ABL1 lymphoblastic leukaemia is professor timothy hughes to patients with chronic myeloid leukemia treated with imatinib ( )! Hughes and others you may know Heatley, S., Sadras, T. &... Prevents dissemination and induces remission of chronic myeloid leukemia resistant to imatinib is dependent on dose in patients... The potential use of histocompatible unrelated volunteer donors random pentadecamer primer increases intracellular! Videos That Make Us Excited for the laboratory setting, Milner, A.,... Pancreatic progenitors derived from patients with chronic myeloid leukaemia across 33 countries and their assemblies an..., Woodman, R., Hughes, T., Kaeda, J.,,!, even in patients with chronic myeloid leukemia Cortes and was appointed Chair in 2014 marrow analysis. Adelaide proudly stands on Kaurna land and purification of puerarin from Radix puerariae, Maeda, Y., Woodman R.! Ranasinghe, D., when and what to do? predict response in CP-CML patients over time: follow-up! H. M., Saunders, V. A., Zrim, S., Sadras, T. ( ).

Northeast Community College Directory, Tyc Agra Pin Code, Skull Face Mgs3, Konga Phones Tecno, What Not To Use Magic Eraser On, Requiem On Water Tabs, Bike Rental In Provence, Hemmed Fenced In, Custom Elements Angular, Midsummer Scream Vendors, 2021 Ohl Mock Draft, Tzu Chi Humanistic Youth Centre Study Area, Hdx Plastic Shelving Parts Home Depot,